Speakers

Speaker line-up of 2021

Aleks Engel

Aleks Engel

Partner, Novo Holding & Director, REPAIR Impact Fund
Anders Karlén

Anders Karlén

Professor in Computer-Aided Drug Design
Caline Mattar

Caline Mattar

Assistant Professor of Medicine, Washington University in St Louis, US

Christoph Dehio

Full Professor of Molecular Microbiology, Director of National Centre of Competence in Research (NCCR) “AntiResist”
Colm Leonard

Colm Leonard

Consultant Clinical Adviser/Consultant Thoracic Physician/Honorary Professor of Respiratory Medicine, National Institute of Health and Care Excellence UK & Manchester University NHS Foundation Trust
David Barros-Aguirre

David Barros-Aguirre

VP, Head of GSK Global Health Pharma R&D Unit, Tres Cantos, Spain
David P. Luci

David P. Luci

President & CEO of Acurx Pharmaceuticals, Inc.
Deborah O’Neil

Deborah O’Neil

CEO, NovaBiotics Ltd & Board Member, BEAM Alliance

Douglas Häggström

Manager INCATE, University of Basel
Enrico Baraldi

Enrico Baraldi

Professor of Industrial Engineering and Management, Uppsala University (Sweden) & Project manager, PLATINEA – Platform for Innovation of Existing Antibiotics (Sweden)
Erin Duffy

Erin Duffy

Chief of Research & Development, CARB-X
Greg Frank

Greg Frank

Director Global Public Policy, MSD
Igor Orshanskiy

Igor Orshanskiy

Director, Business Development & Alliance Management, AiCuris Anti-infective Cures GmbH
Isabelle Bekeredjian-Ding

Isabelle Bekeredjian-Ding

Head of the Microbiology Division at Paul-Ehrlich-Institut (PEI)
Janet Hemingway

Janet Hemingway

Founding Director of the Infection Innovation Consortium (iiCON)
Jeremy Knox

Jeremy Knox

Policy lead, drug-resistant infections, Wellcome Trust
Jessica Boname

Jessica Boname

Head of Antimicrobial Resistance, Medical Research Council (MRC), United Kingdom Research & Innovation (UKRI)
Jürgen Popp

Jürgen Popp

Chair for Physical Chemistry at Friedrich-Schiller University Jena & Scientific director of Leibniz Institute of Photonic Technology, Jena
Justin Yang

Justin Yang

Catalyst Office Director in the Division of Research, Innovation, and Ventures (DRIVe) within the Biomedical Advanced Research and Development Authority (BARDA)
Kathryn L. Talkington

Kathryn L. Talkington

Director, Health Programs, The Pew Charitable Trusts, Washington, DC

Kevin Outterson

Austin B Fletcher Professor, Boston University, and Executive Director & Principal Investigator, CARB-X

Marc Gitzinger

CEO, BioVersys AG & President, BEAM Alliance
Marco Cavaleri

Marco Cavaleri

Head of Biological Health Threats and Vaccines Strategy, EMA
Peter Beyer

Peter Beyer

Unit Head, Impact Initiatives and Research Coordination, AMR Division

Peter Jackson

Executive director, Infex Therapeutics
Philippe Villain-Guillot

Philippe Villain-Guillot

CEO Nosopharm
Thomas B. Cueni

Thomas B. Cueni

Director General, IFPMA